Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The study, conducted by Professor Douglas Hanahan’s team, demonstrated that blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model, suggesting broader implications for cancer treatment. Clinical data supports these findings, showing nadunolimab’s ability to reduce immunosuppressive cells and improve immunotherapy outcomes, potentially enhancing Cantargia’s position in the oncology market.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases, utilizing a platform centered on the protein IL1RAP. Their primary oncology program involves the antibody nadunolimab, which is being clinically studied in combination with chemotherapy for cancers such as pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Additionally, Cantargia is working on CAN10, an antibody targeting autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.